# Nanolatis Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanolatis-co

- Industry: Semiconductors
- Headquarters: Suwon-si, South Korea
- Website: www.nanolatis.com/
- Latest round: Seed (Jul 15, 2025)
- Investors on record: 1

## About

Based in 2024, Nanolatis Co., Ltd. operates as a developer of innovative sensor solutions focused on the biopharmaceutical sector, enhancing quality control through advanced electronic sensor technologies.Nanolatis Co., Ltd. specializes in providing sensor solutions specifically designed for the biopharmaceutical industry. Founded in 2024 and headquartered in Suwon-si, South Korea, the company has engaged in one deal as of July 2025. The founder's background information is not specified.NANOLATIS specializes in the development and provision of innovative sensor solutions tailored for the biopharmaceutical sector. Their core offerings include electronic sensor tags and management solutions utilizing advanced materials that are sensitive to the state of biomaterials. These products enhance quality control throughout the biopharmaceutical supply chain, from manufacturing and transportation to storage and pre-administration stages. The electronic tags, which incorporate low-power circuits and energy-harvesting capabilities, are employed in quality management systems to ensure the integrity of bio products by monitoring environmental conditions in real-time. NANOLATIS serves a diverse client base within the biopharmaceutical industry, with applications extending to manufacturers, logistics providers, and healthcare institutions across global markets, including North America, Europe, and Asia.NANOLATIS generates revenue through a combination of direct sales and partnerships within the biopharmaceutical sector. The company’s revenue model is primarily structured around B2B transactions, wherein they engage with manufacturers and distributors who integrate NANOLATIS's electronic sensor tags and management solutions into their operational workflows. These transactions typically involve one-time purchases or contracts for services that include installation and ongoing support for their technologies. Specific pricing plans for their flagship products are structured to accommodate the varying needs of clients, emphasizing the value of real-time monitoring and data analysis to enhance quality assurance processes. This approach fosters long-term relationships and facilitates continuous improvement of biopharmaceutical management practices for their clients.In July 2025, Nanolatis Co., Ltd. raised an undisclosed amount of Seed funding from new investor Korea Investment Accelerator. The company plans to utilize this funding to advance the development of next-generation sensor solutions and enhance its market presence. Upcoming products are expected to focus on improved functionalities and greater integration capabilities, with a targeted launch in late 2025. Nanolatis aims to expand into additional markets in Europe and Asia by mid-2026, leveraging its innovative technologies to meet the growing demands of the biopharmaceutical sector.

## Funding rounds

- Seed, Jul 15, 2025 — Korea Investment Accelerator

## Investors

- Korea Investment Accelerator (https://capitalatlas.ai/funds/korea-investment-accelerator) — Seed